Myk-461-005 (Explorer-Hcm): A Randomized, Double-Blind, Placebo-Controlled Clinical Study To Evaluate Mavacamten (Myk-461) In Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Posted Date: Jun 9, 2019
- Investigator: Richard Becker
- Type of Study: Drug
Hypertrophic Cardiomyopathy (HCM) is a common condition affecting one of every 500 adults in the general population. The classic phenotypic description consisting of a hypertrophied, non-dilated, left ventricular (LV) cavity with normal or supernormal systolic function has undergone a revision over the past two decades to include several common phenotypic variations such as HCM with apical aneurysms and progressive left ventricular remodeling, dilation and systolic dysfunction referred to as end-stage HCM. Many patients have symptomatic obstructive HCM. Despite progress in the diagnosis and management of HCM, specific drug treatments do not currently exist. Mavacamten, a first-in-class drug designed specifically for HCM is being tested in the EXPLORER study.
Patients With A Diagnosis Of Symptomatic Obstructive Hypertrophic Cardiomyopathy Are Eligable For Screening.
For More Information:
Richard C. Becker, Md